Dr. Edus Houston Warren

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Clinical Research Division
Program in Immunology
Associate Member
University of Washington
School of Medicine
Medicine
Medical Oncology
Associate Professor
Professional Headshot of Edus Houston Warren

Mailing Address

Fred Hutchinson Cancer Research Center
1100 Fairview Avenue N.
P.O. Box 19024
D3-100
Seattle, Washington 98109-1024
United States

Contact Information

Phone: (206) 667-6441
Fax: (206) 667-7983
Mobile: (206) 399-9497
ehwarren@u.washington.edu

Qualifications

M.D., Harvard University, 1991.
Ph.D., Harvard University, Neurobiology, 1988.
A.B., Harvard University, Applied Mathematics, 1982.

Expertise and Research Interests

My primary laboratory and clinical interest is the cellular and molecular dissection of antitumor immune responses, so that these immune responses can be exploited to clinical advantage. In particular, the research in my laboratory is focused on the mechanisms and target molecules associated with the graft-versus-tumor (GVT) reaction that occurs after allogeneic hematopoietic cell transplantation for hematologic malignancies and selected solid tumors. My lab has extensive experience with the characterization and manipulation of human CD8+ and CD4+ T cells, as well as with the identification of antigens recognized by CD8+ cytotoxic T lymphocyte (CTL) clones using a variety of techniques, including cDNA expression cloning, genetic linkage analysis, and peptide elution/HPLC fractionation. In the clinical realm, I have several years' of experience serving as the Principal Investigator on an IRB- and FDA-approved Phase I clinical trial of adoptive therapy with CD8+ minor histocompatibility antigen-specific CTL clones for the treatment of acute leukemia or high-grade myelodysplasia that recurs after HLA-identical allogeneic hematopoietic cell transplantation. I am an Attending Physician on the Allogeneic Transplant Service at the Seattle Cancer Care Alliance.

Future Research

The primary scientific focus of the Warren laboratory at present is the dissection at a cellular and molecular level of the mechanisms that mediate both graft-versus-host disease (GVHD) and graft-versus-leukemia/ graft-versus-tumor reactions after MHC-matched allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT plays an important role in the treatment of hematologic malignancies such as myelodysplasia, acute myelogeneous leukemia (AML) and acute lymphoblastic leukemia (ALL), and better understanding of the biology of both GVHD and GVL will likely lead to improved transplant outcomes for the increasing number of patients undergoing this procedure. Data from several recently completed or still ongoing clinical trials suggests that metastatic renal cell carcinoma (RCC), a common solid tumor that is refractory to standard radiation and chemotherapy, may also be susceptible to an immune-mediated graft-versus-tumor effect after allogeneic HCT. A new area of interest in my laboratory is investigation of the mechanisms underlying regression of RCC after allogeneic HCT, with the hope that these studies will ultimately lead to the development of novel therapies for RCC that are based on the adoptive transfer of tumor-reactive T cells. T cell responses against peptides derived from self proteins such as WT1 may also be pathogenic in certain clinical settings such as early-stage myelodysplasia, and my laboratory is currently completing a collaborative study with Dr. Joachim Deeg at the FHCRC that investigated changes in the peripheral blood and bone marrow T cell repertoire associated with response of early-stage myelodysplasia to immune-suppressive therapy with anti-thymocyte globulin (ATG) and etanercept (Enbrel).

Keywords

COS Keywords:

Cancer or Carcinogenesis, Cell Transplantation, Hematology, Immunology, Immunotherapy, Neurobiology, Oncology.

Additional Terms:

Oncology.

Languages

(Reading, Writing, Speaking)

English: (Fluent, Fluent, Fluent)
French: (Functional, Functional, Functional)
German: (Basic, Basic, Basic)
Spanish: (Basic, Basic, Basic)

Honors and Awards

2008-2013, Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund
2000-2005, Lilly Clinical Investigator Award, Damon Runyon Cancer Research Foundation
1999-2000, Mentored Clinical Scientist Development (K08) Award, National Institutes of Health (NIH)
1996-1997, Florence A. Carter Fellowship in Leukemia Research, American Medical Association Education and Research Fund
1996-1998, International Fellowship in Research on Leukemia and Allied Diseases, Lady Tata Memorial Trust
1995-1995, Molecular Biology in Clinical Oncology Workship, American Association for Cancer Research
1979-1982, Harvard College Scholarship, Harvard College
1977-1977, National Merit Scholarship, Monsanto Corporation

Previous Positions

2003-2004, Visiting Scientist, Ludwig Institute for Cancer Research, Brussels Branch
2001-2007, Assistant Professor of Medicine, University of Washington, Department of Medicine
2001-2007, Assistant Member, Fred Hutchinson Cancer Research Center, Program in Immunology, Clinical Research Division
1998-2001, Associate in Clinical Research, Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center
1997-2001, Acting Instructor, University of Washington, Department of Medicine
1996-1998, Research Associate, Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center
1993-1996, Fellow, Medical Oncology, University of Washington
1992-1993, Resident, Internal Medicine, Massachusetts General Hospital
1991-1992, Intern, Internal Medicine, Massachusetts General Hospital

Funding Received

  • National Institutes of Health (NIH): P01 CA 18029-31 (Appelbaum) Improve the outcome of allogeneic hematopoietic stem cell transplantation in the treatment of hematologic malignancies, 2007 to 2012.
  • University of Washington Royalty Research Fund: 3896 (Warren) Identification of genomic loci associated with graft-versus-leukemia activity after allogeneic hematopoietic cell transplantation, 2007 to 2008.
  • National Institutes of Health (NIH): 5 P30 CA015704-34 (Hartwell) FHCRC CCSG Pilot (Warren) Characterization of tumor-and lymph node-infiltrating CD3* lymphocytes in stage III colorectal carcinoma, 2007 to 2007.
  • J. Orin Edson Fund for Immunotherapy (Warren): Characterization fo tumor-and lymph node-infiltrating CD3* lymphocytes in stage III colorectal carcinoma, 2007 to 2007.
  • National Institutes of Health (NIH): R21 CA119599-01 (Deeg) WI1 Expression in patients treated with MDS treat with ATG and TNF-a blockade, 2005 to 2007.
  • Lauri Strauss Leukemia Foundation: FDN TE 4153 (Warren) Transcription factors in hematopoietic stem cells as targets for leukemia immunotherapy, 2005 to 2006.
  • National Institutes of Health (NIH): Allogeneic T Cell Responses Against Renal Cell Carcinoma, 1 R01 CA106512 (PI), 2004 to 2009.
  • Damon Runyon Cancer Research Foundation: FND TE 3172 (Warren) Antigen-specific T-cell therapy for leukemia, 2000 to 2005.

Publications

  • Tykodi SS, Fujii N, Vigneron N, Lu SM, Mito JK, Miranda MX, Chou J, Voong LN, Thompson JA, Sandmaier BM, Cresswell P, Van den Eynde B, Riddell SR, Warren EH (Aug 2008) C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients., Clinical cancer research : an official journal of the American Association for Cancer Research, 14 (16), 5260-9 Abstract
  • Rosinski KV, Fujii N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, Gibbs JS, Radich JP, Akatsuka Y, Van den Eynde BJ, Riddell SR, Warren EH (May 2008) DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells., Blood, 111 (9), 4817-26 Abstract
  • Campregher PV, Gooley T, Scott BL, Moravec C, Sandmaier B, Martin PJ, Deeg HJ, Warren EH, Flowers ME (Nov 2007) Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation., Bone marrow transplantation, 40 (10), 965-71 Abstract
  • Terakura S, Murata M, Warren EH, Sette A, Sidney J, Naoe T, Riddell SR (May 2007) A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403., Transplantation, 83 (9), 1242-8 Abstract
  • Deeg HJ, Maris MB, Scott BL, Warren EH (Oct 2006) Optimization of allogeneic transplant conditioning: not the time for dogma., Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 20 (10), 1701-5 Abstract
  • Warren EH, Vigneron NJ, Gavin MA, Coulie PG, Stroobant V, Dalet A, Tykodi SS, Xuereb SM, Mito JK, Riddell SR, Van den Eynde BJ (Sep 2006) An antigen produced by splicing of noncontiguous peptides in the reverse order., Science (New York, N.Y.), 313 (5792), 1444-7 Abstract
  • Brickner AG, Evans AM, Mito JK, Xuereb SM, Feng X, Nishida T, Fairfull L, Ferrell RE, Foon KA, Hunt DF, Shabanowitz J, Engelhard VH, Riddell SR, Warren EH (May 2006) The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL., Blood, 107 (9), 3779-86 Abstract
  • Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R (May 2006) Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 (5), 573-84 Abstract
  • Riddell SR, Bleakley M, Nishida T, Berger C, Warren EH (Jan 2006) Adoptive transfer of allogeneic antigen-specific T cells., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 (1 Suppl 1), 9-12 Abstract
  • Berger C, Flowers ME, Warren EH, Riddell SR. (2006) Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation, Blood, 107, 2294-2302
  • Warren EH (2006) Minor histocmpatibility antigens in allogeneic hematopoietic cell transplantation, Current Opinion in Organ Transplantation, 11, 31-36
  • Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM, Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma After Nonmyeloablative Conditioning: Toxicity, Clinical Response, and Immunological Response to Minor Histocompatibility Antigens., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research., 10(23), 7799-811, Dec 2004 Abstract
  • Torikai H, Akatsuka Y, Miyazaki M, Warren EH, Oba T, Tsujimura K, Motoyoshi K, Morishima Y, Kodera Y, Kuzushima K, Takahashi T (Dec 2004) A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene., Journal of Immunology, 173 (11), 7046-54 Abstract
  • Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR, Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants, Blood, 103(1), 347-52, January 2004 Abstract
  • Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR, Allogeneic hematopoietic stem cell transplantation for myelofibrosis, Blood, 102(12), 3912-8, December 2003 Abstract
  • Akatsuka Y, Warren EH, Gooley TA, Brickner AG, Lin MT, Hansen JA, Martin PJ, Madtes DK, Engelhard VH, Takahashi T, Riddell SR, Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identica, British Journal of Haematology, 123(4), 671-5, November 2003 Abstract
  • Riddell SR, Berger C, Murata M, Randolph S, Warren EH, The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation, Blood Reviews, 17(3), 153-62, September 2003 Abstract
  • Murata M, Warren EH, Riddell SR, A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion, Journal of Experimental Medicine, 197(10), 1279-89, May 2003 Abstract
  • Warren EH, Otterud BE, Linterman RW, Brickner AG, Engelhard VH, Leppert MF, Martin PJ, Riddell SR, Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens, Tissue Antigens, 59(4), 293-303, April 2002 Abstract
  • Riddell SR, Murata M, Bryant S, Warren EH, T-cell therapy of leukemia, Cancer Control : Journal of the Moffitt Cancer Center, 9(2), 114-22, 2002 Abstract
  • Brickner AG, Warren EH, Caldwell JA, Akatsuka Y, Golovina TN, Zarling AL, Shabanowitz J, Eisenlohr LC, Hunt DF, Engelhard VH, Riddell SR, The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing, Journal of Experimental Medicine, 193(2), 195-206, 2001 Abstract
  • Warren EH, Gavin MA, Simpson E, Chandler P, Page DC, Disteche C, Stankey KA, Greenberg PD, Riddell SR, The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen, Journal of Immunology, 164(5), 2807-14, 2000 Abstract
  • Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR, CD8 minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells, Proceedings of the National Academy of Sciences (USA), 96(15), 8639-44, 1999 Abstract
  • Warren EH, Gavin M, Greenberg PD, Riddell SR, Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation, Current Opinion in Hematology, 5(6), 429-33, November 1998 Abstract
  • Warren EH, Greenberg PD, Riddell SR, Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution, Blood, 91(6), 2197-207, 1998 Abstract

Profile Details

Last Updated: 9/7/2008

COS Expertise ID #345998
Reference this profile directly: http://myprofile.cos.com/ehwarren